Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:ELYM NASDAQ:FENC NASDAQ:INDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.85+5.7%$2.38$1.60▼$4.94$100.28M3.221.90 million shs1.88 million shsELYMEliem Therapeutics$13.36+2.1%$10.90$2.35▼$11.55$397.49M-0.39486,688 shs1.16 million shsFENCAdherex Technologies$10.75-2.5%$8.72$5.65▼$11.31$384.80M1.08279,690 shs235,808 shsINDPIndaptus Therapeutics$3.00-2.0%$2.62$0.92▼$13.40$346.52M1.252.96 million shs192,772 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+5.71%+14.91%-16.67%-20.60%-25.40%ELYMEliem Therapeutics+2.14%+9.69%+21.90%+104.28%+1,032.20%FENCAdherex Technologies-2.54%+4.37%+8.26%+67.71%+29.52%INDPIndaptus Therapeutics-1.96%-19.14%+70.45%+76.47%-71.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.85+5.7%$2.38$1.60▼$4.94$100.28M3.221.90 million shs1.88 million shsELYMEliem Therapeutics$13.36+2.1%$10.90$2.35▼$11.55$397.49M-0.39486,688 shs1.16 million shsFENCAdherex Technologies$10.75-2.5%$8.72$5.65▼$11.31$384.80M1.08279,690 shs235,808 shsINDPIndaptus Therapeutics$3.00-2.0%$2.62$0.92▼$13.40$346.52M1.252.96 million shs192,772 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+5.71%+14.91%-16.67%-20.60%-25.40%ELYMEliem Therapeutics+2.14%+9.69%+21.90%+104.28%+1,032.20%FENCAdherex Technologies-2.54%+4.37%+8.26%+67.71%+29.52%INDPIndaptus Therapeutics-1.96%-19.14%+70.45%+76.47%-71.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$10.00440.54% UpsideELYMEliem Therapeutics 0.00N/AN/AN/AFENCAdherex Technologies 2.71Moderate Buy$15.4043.26% UpsideINDPIndaptus Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BDTX, ELYM, INDP, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/25/2026FENCAdherex Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026FENCAdherex Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $16.005/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.004/23/2026BDTXBlack Diamond Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/21/2026FENCAdherex Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.51$0.56 per share3.32$1.97 per share0.94ELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AFENCAdherex Technologies$44.64M8.40N/AN/A$1.04 per share10.34INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)ELYMEliem Therapeutics-$35.12M-$0.53N/AN/AN/AN/A-47.03%-45.97%N/AFENCAdherex Technologies-$9.74M-$0.29N/A11.68N/A-17.12%-43.87%-11.35%8/13/2026 (Estimated)INDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)Latest BDTX, ELYM, INDP, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/14/2026Q1 2026FENCAdherex Technologies-$0.02$0.01+$0.03$0.01$13.90 million$15.11 million5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46ELYMEliem TherapeuticsN/A60.4160.41FENCAdherex TechnologiesN/A6.986.78INDPIndaptus TherapeuticsN/A2.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%ELYMEliem Therapeutics69.76%FENCAdherex Technologies55.51%INDPIndaptus Therapeutics7.06%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%ELYMEliem Therapeutics4.70%FENCAdherex Technologies10.73%INDPIndaptus Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableFENCAdherex Technologies1034.89 million31.14 millionOptionableINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableBDTX, ELYM, INDP, and FENC HeadlinesRecent News About These CompaniesIndaptus Therapeutics (NASDAQ:INDP) Upgraded to Hold at Wall Street ZenJune 27, 2026 | americanbankingnews.comIndaptus Therapeutics Announces Private Placement of Common StockJune 24, 2026 | tipranks.comReviewing United Therapeutics (NASDAQ:UTHR) and Indaptus Therapeutics (NASDAQ:INDP)June 22, 2026 | americanbankingnews.comAbbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. StockholdersJune 17, 2026 | globenewswire.comIndaptus Therapeutics Announces Recent Board and Leadership ChangesJune 5, 2026 | tipranks.comIndaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertaintyJune 4, 2026 | quiverquant.comQIndaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comIndaptus Therapeutics Adds Independent Directors Amid Board RefreshApril 23, 2026 | tipranks.comIndaptus Therapeutics Appoints David Natan to BoardJanuary 8, 2026 | tipranks.comBiolojic Design appoints new chief medical officerJanuary 8, 2026 | thepharmaletter.comTIndaptus Therapeutics announces upcoming board leadership transitionJanuary 3, 2026 | msn.comIndaptus Therapeutics enters $6M securities purchase agreement with David LazarDecember 29, 2025 | msn.comIndaptus Therapeutics stock falls after $6 million securities dealDecember 29, 2025 | za.investing.comWhy did INDP stock gain 12% today?December 29, 2025 | msn.comIndaptus Therapeutics Secures $6 Million Investment from David E. Lazar, Appoints Him Co-CEO and ChairmanDecember 29, 2025 | quiverquant.comQIndaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarDecember 29, 2025 | globenewswire.comIndaptus Therapeutics (INDP) Price Target Decreased by 60.00% to 10.20November 17, 2025 | msn.comIndaptus Therapeutics to Present Advances in Allogeneic Immune Cell Therapy at 3rd Donor Selection & Cell Source SummitNovember 17, 2025 | quiverquant.comQIndaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source SummitNovember 17, 2025 | globenewswire.comIndaptus Therapeutics Reports Q3 2025 Financial Results and Corporate UpdateNovember 12, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, ELYM, INDP, and FENC Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.85 +0.10 (+5.71%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$1.86 +0.01 (+0.54%) As of 06/30/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Eliem Therapeutics NASDAQ:ELYM$13.36 +0.28 (+2.14%) As of 06/29/2026Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Adherex Technologies NASDAQ:FENC$10.75 -0.28 (-2.54%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$10.75 0.00 (0.00%) As of 06/30/2026 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Indaptus Therapeutics NASDAQ:INDP$3.00 -0.06 (-1.96%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$2.90 -0.10 (-3.33%) As of 06/30/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
